YOU SEARCHED BY...
SEARCH BY...
States
- California(12)
- Florida(1)
- Indiana(2)
- Kansas(1)
- Maryland(3)
- Massachusetts(6)
- Michigan(4)
- Minnesota(1)
- New Jersey(13)
- New York(2)
- North Carolina(2)
- Ohio(1)
- Oklahoma(1)
- Pennsylvania(13)
- Texas(1)
- Utah(1)
- Vermont(1)
- Washington(1)
Contract Service Directory
BioIVT
Company Headquarters
123 Frost Street,
Suite 115
Westbury, NY 11590
United States
Contract Service Directory
Content From BioIVT
-
[WEBINAR] Understanding BioIVT’s New Tiered Study Options: What Does it Mean for You?
This webinar will provide insight into the industry trends and compound progression strategies behind their tiered design.Sponsored Content Released on 07.14.2023
-
In Vitro Aspects of ICH M12, Industry and Technology
Download the Presentations from the 2023 Advanced In Vitro ADME Strategies: ICH Guidelines & Novel Methodologies Symposium.Literature / Brochures Released on 07.14.2023
-
Improving In Vivo Predictions from In Vitro Hepatocyte Models
Download the Presentations from the 2023 Advanced In Vitro ADME Strategies: ICH Guidelines & Novel Methodologies Symposium.Literature / Brochures Released on 07.14.2023
-
DDI Potential of Major Pharmaceutical Excipients on Transporters and Enzymes
Download the Presentations from the 2023 Advanced In Vitro ADME Strategies: ICH Guidelines & Novel Methodologies Symposium.Literature / Brochures Released on 07.14.2023
-
SAFETY FIRST: Assessing Drugs Early Can Preclude Regulatory and Health Issues
A Guide to When & Why to Evaluate ADME/PK & Drug-Drug InteractionsSponsored Content Released on 07.14.2023
-
ADME/PK & DDI Best Practices Industry Survey Results & Infographic
Read about when most researchers are performing ADME/PK & DDI testing, see what the top 4 repercussions and risks are from postponing and more.Infographics Released on 07.14.2023
-
Four Ways to Optimize Preclinical In Vitro Data to Mitigate Risk of Late-Stage Clinical Failure
When it comes to planning studies for your drug’s preclinical development, even more due diligence is required because the stakes could be huge.Company Blog Released on 07.14.2023
-
Timing of In Vitro Studies: Early, Thorough ADME for Your Compound’s Success
FDA and other regulatory bodies around the world need to see that a compound will be safe to give to patients in a clinical settingCompany Blog Released on 07.14.2023
-
4 Ways De-Risking Maximizes Compound Value
View BioIVT's infographic to learn about how you can leverage your data to showcase your compound in ways that will maximize its value.Infographics Released on 07.14.2023
-
A Guide to In Vitro CYP Inhibition Studies
Elements of Study Design and Important Considerations in Data AnalysisSponsored Content Released on 07.14.2023
-
When, Why and How to Conduct CYP2C Induction Studies
Why is measuring CYP induction important?Company Blog Released on 07.14.2023
-
Why Do Most Polled Researchers Run Red Blood Cell Partitioning Studies with Plasma Protein Binding?
Pharmacokinetic (PK) parameters of new drug candidates are traditionally determined by measuring drug concentration in plasma.Company Blog Released on 07.14.2023
-
In Vitro Strategies for Evaluating Non-CYP Metabolism Pathways
An overview of these pathways including a discussion of regulatory interest, case examples, in vitro reaction phenotyping approaches and more.Sponsored Content Released on 07.14.2023
-
Are In Vitro Drug Metabolism and Drug-Drug Interaction Studies Critical for an IND?
A Guide to What, Why & When to Conduct ADME Studies.Company Blog Released on 07.13.2023
